Editorial: Targeting Urgency in IBD-A Historical Divide.
Authors' response to letter to editor-silencing GATA3: DNAzymes enter the therapeutic landscape of ulcerative colitis.
Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials.
Intestinal barrier healing is superior to transmural healing to prevent disease progression in clinical remittent patients with inflammatory bowel disease.
Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.
Successful treatment of severe retroauricular pyoderma gangrenosum with upadacitinib in a patient with Crohn's disease and a history of cerebral venous sinus thrombosis.
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis.
Clinical Trial Endpoints for Perianal Fistulizing Crohn's Disease.
Author Correction: E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis.
Tools and advanced imaging technologies for assessing intestinal epithelial barrier integrity: a systematic review.
P1159 Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials
Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling
Epithelial OPA1 links mitochondrial fusion to inflammatory bowel disease
Epithelial OPA1 links mitochondrial fusion to inflammatory bowel disease.
Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD
Diagnosis and Management of Upper Gastrointestinal Involvement in Adult Patients With Crohn’s Disease: A Systematic Review
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial.
Intestinal interstitial fluid isolation provides novel insight into the human host-microbiome interface
Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD.
Integrin αVβ6: Autoantigen and Driver of Epithelial Remodeling in Colon and Bile Ducts in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.
Metabolic stress sensing by epithelial RXRα links westernization of diet with Crohn’s disease
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.
IL-36 signaling as a drug target in Crohn’s disease patients with IL36RN mutations
Efficacy and safety of risankizumab in patients with moderately to severely active Crohn's disease: interim results from the SEQUENCE open-label extension study.
Superb Microvascular Imaging Is Superior to Doppler Imaging in Ruling Out Ulcerative Colitis Disease Activity.
MRI Volumetric Changes in Perianal Fistulizing Crohn's Disease: Moving Toward a Novel Outcome Measure for Therapeutic Response.
mHealth Use, Preferences, Barriers, and eHealth Literacy Among Patients With Inflammatory Bowel Disease: Survey Study.
Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn's disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment.
Intestinal interstitial fluid isolation provides novel insight into the human host-microbiome interface.